TY - JOUR
T1 - Establishing a hepatitis C continuum of care among HIV/hepatitis C virus‐coinfected individuals in EuroSIDA
AU - on behalf of the EuroSIDA study group
AU - Amele , Sarah
AU - Peters, L
AU - Sluzhynska, M
AU - Yakovlev, M,A
AU - Scherrer, A
AU - Domingo, P
AU - Gerstoft, Jan
AU - Viard, Jean-Paul
AU - Gisinger, M
AU - Flisiak, R
AU - Bhaghani, S
AU - Ristola, M.
AU - Leen, Clifford
AU - Jablonowska, E
AU - Wandeler, G
AU - Stellbrink, Hans-jürgen
AU - Falconer, K
AU - Monforte, Antonella d'Arminio
AU - Horban, Andrzej
AU - Rockstroh, Juergen K.
AU - Lundgren, J. D
AU - Mocroft, Amanda
PY - 2019/2/8
Y1 - 2019/2/8
N2 - Objectives: To establish a methodology for evaluating the hepatitis C continuum of care in HIV/HCV co-infected individuals and to characterise the continuum in Europe on 1/1/2015, prior to widespread access to direct-acting antiviral (DAA) therapy.
Methods: Stages included in the continuum were: anti-HCV antibody positive, HCV-RNA tested, currently HCV-RNA positive, ever HCV-RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV-RNA test, and cure. Sustained virologic response (SVR) could only be assessed for those with a follow-up HCV-RNA test, and was defined as a negative HCV-RNA result measured more than 12 or 24 weeks after stopping treatment.
Results: Following stages of the HCV continuum of care were defined: anti-HCV positive (n=5173), HCV-RNA tested (4207/5173; 81.3%), currently HCV-RNA positive (3179/5173; 61.5%), ever HCV-RNA positive (n=3876), initiated HCV treatment (1693/3876; 43.7%), completed HCV treatment (1598/3876; 41.2%), follow-up HCV-RNA test to allow SVR assessment (1195/3876; 30.8%), and cure (629/3876; 16.2%). The proportion that achieved SVR was 52.6% (629/1195). There were significant differences between regions at each stage of the continuum (p<0.0001).
Conclusions: In the proposed HCV continuum of care for HIV/HCV co-infected individuals we found major gaps at all stages, with almost 20% of anti-HCV positive individuals having no documented HCV-RNA test and a low proportion achieving SVR, in the pre-DAA era.
AB - Objectives: To establish a methodology for evaluating the hepatitis C continuum of care in HIV/HCV co-infected individuals and to characterise the continuum in Europe on 1/1/2015, prior to widespread access to direct-acting antiviral (DAA) therapy.
Methods: Stages included in the continuum were: anti-HCV antibody positive, HCV-RNA tested, currently HCV-RNA positive, ever HCV-RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV-RNA test, and cure. Sustained virologic response (SVR) could only be assessed for those with a follow-up HCV-RNA test, and was defined as a negative HCV-RNA result measured more than 12 or 24 weeks after stopping treatment.
Results: Following stages of the HCV continuum of care were defined: anti-HCV positive (n=5173), HCV-RNA tested (4207/5173; 81.3%), currently HCV-RNA positive (3179/5173; 61.5%), ever HCV-RNA positive (n=3876), initiated HCV treatment (1693/3876; 43.7%), completed HCV treatment (1598/3876; 41.2%), follow-up HCV-RNA test to allow SVR assessment (1195/3876; 30.8%), and cure (629/3876; 16.2%). The proportion that achieved SVR was 52.6% (629/1195). There were significant differences between regions at each stage of the continuum (p<0.0001).
Conclusions: In the proposed HCV continuum of care for HIV/HCV co-infected individuals we found major gaps at all stages, with almost 20% of anti-HCV positive individuals having no documented HCV-RNA test and a low proportion achieving SVR, in the pre-DAA era.
U2 - /doi.org/10.1111/hiv.12711
DO - /doi.org/10.1111/hiv.12711
M3 - Article
SN - 1464-2662
JO - HIV Medicine
JF - HIV Medicine
ER -